CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7004 result(s)

CADTH Weekly COVID-19 Update

Last Updated: September 21, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...

Non-Opioid Options for Managing Pain

Last Updated: September 21, 2020
Result type: Tools

Canada is in the midst of an opioid crisis. And even with growing awareness of the risks, opioids continue to be used extensively in the management of pain. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain recommends optimizing non-opioid pharmacotherapy and non-pharmacological therapy rather than a trial of opioids for patien...

erenumab (Aimovig)

Last Updated: September 18, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: erenumab
Indications: Migraine

  • Brand Name: Aimovig
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0578-000
  • Project Status: Complete
  • Submission Type: New

Acute Pain Management: Non-Pharmacological Interventions

Last Updated: September 17, 2020
Result type: Tools

There are many interventions available for acute or sub-acute pain management. They include both pharmacological and non-pharmacological options. Over the last few years, CADTH has been asked to review, through our Rapid Response Service, the clinical effectiveness evidence and the recommendations from evidence-based guidelines for treating vari...

Fecal Microbiota Therapy in Canada: Barriers and Facilitators to Access

Last Updated: September 17, 2020
Result type: Reports
Product Line: Environmental Scans
Research Type: Device

Evidence supports the use of fecal microbiota transplant (FMT) for recurrent Clostridium difficile (C. difficile) infection. Information on the potential of FMT for treating other conditions, such as inflammatory bowel disease, ulcerative colitis, and Crohn disease, is also emerging. Given this, the indications and demand for FMT may increase in...

  • Project Number: ES0341-000

ustekinumab (Stelara/Stelara I.V)

Last Updated: September 14, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ustekinumab
Indications: Ulcerative colitis

  • Brand Name: Stelara/Stelara I.V
  • Manufacturer: Janssen Inc.
  • Project Number: SR0627-000
  • Project Status: Complete
  • Submission Type: New

CADTH Weekly COVID-19 Update

Last Updated: September 14, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...

New at CADTH - September 2020

Last Updated: September 9, 2020
Result type: Reports
Product Line: New at CADTH

News and Events Core Principles for Deliberative Processes in HTA
A new article summarizes discussions held at the 2020 HTAi Global Policy Forum about the core principles for deliberative processes in HTA.Read more on our website. 2020 CADTH Symposium
Great news – our 2020 Symposium will now be held virtually on November 9 and 10. ...